Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 10:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 841 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Hormonal therapy Clear all
Completed Phase 3 Interventional Results available

Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer

NCT00009945
View directory record Official record
Conditions
Breast Cancer
Interventions
clodronate, placebo
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
3,323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
17
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Honolulu, Hawaii + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 5, 2026, 10:52 PM EDT
Enrolling by invitation Phase 3 Interventional

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

NCT05645536
View directory record Official record
Conditions
Breast Cancer
Interventions
TOL2506, Tamoxifen, Letrozole tablets, Anastrozole Tablets, Exemestane Tablets
Drug
Lead sponsor
Tolmar Inc.
Industry
Eligibility
18 Years to 51 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
17
States / cities
Greenbrae, California • Fort Lauderdale, Florida • Lexington, Kentucky + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 5, 2026, 10:52 PM EDT
Completed Phase 2 Interventional

Hormone Therapy Followed By Internal Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer

NCT00032006
View directory record Official record
Conditions
Prostate Cancer
Interventions
brachytherapy, radiation therapy
Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
8
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Urbana, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 5, 2026, 10:52 PM EDT
Recruiting Early Phase 1 Interventional

FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer

NCT04174352
View directory record Official record
Conditions
ERα+ Breast Cancer, ESR1 Gene Mutation
Interventions
Tamoxifen, FES PET/CT
Drug · Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
19 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 5, 2026, 10:52 PM EDT
Completed Phase 3 Interventional

Gabapentin With or Without Antidepressants in Treating Hot Flashes in Women Who Have Had Breast Cancer or Have Concerns About Taking Hormone Therapy

NCT00087399
View directory record Official record
Conditions
Breast Cancer, Hot Flashes
Interventions
gabapentin, antidepressant
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
162
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Augusta, Georgia + 101 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 5, 2026, 10:52 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005810
View directory record Official record
Conditions
Prostate Cancer
Interventions
filgrastim, carboplatin, docetaxel, estramustine phosphate sodium
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
7
States / cities
San Francisco, California • Chicago, Illinois • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 5, 2026, 10:52 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Growth Hormone and Chromosome 18q- and Abnormal Growth

NCT00134420
View directory record Official record
Conditions
Loss of Chromosome 18q, Growth Hormone Deficiency
Interventions
Nutropin AQ, Arginine and Clonidine Stimulation Testing, Growth Factors Laboratory Testing, Neuropsychological Testing
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Up to 18 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2016 · Synced Sep 5, 2026, 10:52 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sleep and IR in Transgender Adolescents

NCT05489159
View directory record Official record
Conditions
Sleep Disorder, Insulin Resistance, Gender Dysphoria
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
12 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Sep 5, 2026, 10:52 PM EDT
Completed Phase 2 Interventional

Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00015977
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSA prostate cancer vaccine, recombinant interleukin-12
Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Sep 5, 2026, 10:52 PM EDT
Terminated Phase 2 Interventional Results available

Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00524589
View directory record Official record
Conditions
Prostate Cancer
Interventions
calcitriol, dexamethasone, protein expression analysis, laboratory biomarker analysis
Dietary Supplement · Drug · Genetic + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Up to 120 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced Sep 5, 2026, 10:52 PM EDT
Completed Phase 2 Interventional

Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005820
View directory record Official record
Conditions
Prostate Cancer
Interventions
nitrocamptothecin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
50
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 5, 2026, 10:52 PM EDT
Terminated Phase 2 Interventional Results available

Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer

NCT00918385
View directory record Official record
Conditions
Prostate Cancer
Interventions
Nilutamide, Dasatinib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Durham, North Carolina • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Sep 5, 2026, 10:52 PM EDT
Completed Phase 2 Interventional

BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00040755
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Bone Metastases, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
rebimastat, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Male only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Sep 5, 2026, 10:52 PM EDT
Completed Phase 2 Interventional Results available

Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.

NCT00921115
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
Fulvestrant, Anastrazole
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Sep 5, 2026, 10:52 PM EDT
Completed No phase listed Observational

Biomarkers in Blood Samples From Older Breast Cancer Survivors

NCT01138345
View directory record Official record
Conditions
Breast Cancer
Interventions
gene expression analysis, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis, medical chart review, questionnaire administration
Genetic · Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
50 Years and older · Female only
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 26, 2014 · Synced Sep 5, 2026, 10:52 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Multi-omic Approach to Evaluate and Characterize the Polycystic Ovary Syndrome (PCOS) Phenotype

NCT04981275
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
No intervention study
Other
Lead sponsor
Onegevity Health
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Sep 5, 2026, 10:52 PM EDT
Completed Phase 1 Interventional

PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer

NCT00508586
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
PTC299
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Indianapolis, Indiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Sep 5, 2026, 10:52 PM EDT
Not yet recruiting Not applicable Interventional

Feasibility of 'Exercise for CAncer Patients and Healthy EAting Timeframes' .

NCT07529353
View directory record Official record
Conditions
Breast Cancer, Cancer Related Fatigue
Interventions
EXCAP Exercise Program, 10-Hour Healthy Eating Timeframe (hEAT)
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 5, 2026, 10:52 PM EDT
Withdrawn Phase 2 Interventional

Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients

NCT02678520
View directory record Official record
Conditions
Prostate Cancer
Interventions
3-D Conformal Radiation Therapy, Intensity Modulated Radiation Therapy, Casodex, Zoladex , Lupron
Radiation · Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fairway, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Sep 5, 2026, 10:52 PM EDT
Completed Phase 2 Interventional

ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation

NCT00063310
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Leuprolide acetate
Drug
Lead sponsor
Voyager Pharmaceutical Corporation
Industry
Eligibility
65 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Sun City, Arizona • Fort Lauderdale, Florida • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2009 · Synced Sep 5, 2026, 10:52 PM EDT
Completed Phase 2 Interventional

Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer

NCT00003669
View directory record Official record
Conditions
Endometrial Cancer
Interventions
arzoxifene hydrochloride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
10
States / cities
Pasadena, California • Columbia, Missouri • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Sep 5, 2026, 10:52 PM EDT
Terminated Not applicable Interventional

Electro-acupuncture and Assisted Reproductive Technology

NCT01481090
View directory record Official record
Conditions
Infertility
Interventions
Acupuncture, Electro-Acupuncture
Procedure
Lead sponsor
National University of Health Sciences
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Chicago, Illinois • Lombard, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 5, 2026, 10:52 PM EDT
Recruiting Phase 2 Interventional

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer

NCT07483307
View directory record Official record
Conditions
Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, ER+ Breast Cancer, Lobular Breast Carcinoma
Interventions
Neoadjuvant endocrine therapy
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
50 Years and older · Female only
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 5, 2026, 10:52 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Vitamin D and Physical Activity on Bone Health

NCT01419730
View directory record Official record
Conditions
Bone Metabolism Biomarkers, Bone Mineral Density, Physical Fitness
Interventions
Vitamin D3, Physical Activity
Drug · Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 5, 2026, 10:52 PM EDT